Abstract. 1α,25-dihydroxyvitamin D 3 (VD 3 ) and the EB1089 analog are well known for their roles in the modulation of proliferation and the differentiation of several malignant cells. In addition, VD 3 or EB1089 displayed a high disposal of oxidant features and the ability to cause release of reactive oxygen species (ROS). We attempted to enhance HL60 cell differentiation and to limit ROS generation, by the association of deltanoids with doxorubicin and the antioxidants catalase (CAT), superoxide dismutase (SOD) and N-acetyl cystein (NAC). Differentiation of HL60 cells into monocytic lineage was studied by expression of mRNA, protein CD14 and functional differentiation by the nitroblue tetrazolium assay. The 2',7'-dichlorodihydrofluorescein diacetate (H 2 -DCFDA) dye allowed to evaluate in situ ROS generation. When associated with 0.1 nM EB1089, 15 nM doxorubicin induced an increase of differentiated cell percentage from 29% to 87% and did not affect VD 3 -treated cells. The association with doxorubicin also induced a significant increase of ROS release (p<0.05) versus VD 3 and EB1089-treated cells. These results correspond to additivity of individual effects of doxorubicin and deltanoids. Antioxidant agents (10 nM NAC, 50 U/ml SOD or 2000 U/ml CAT) were associated with 10 nM VD 3 or 1 nM EB1089 for 72 h. Compared to VD 3 and EB1089 treatments, associations with antioxidants induced a slight increase of differentiated cells and a significant increase of CD14 mRNA. The highest differentiation effect occurred in the case of the EB1089-NAC association. Antioxidants induced a decrease (p<0.05) in ROS release generated by VD 3 or EB1089 near the level of untreated cells. Thus, antioxidant agents demonstrated a protective effect against VD 3 and EB1089 oxidative cytotoxicity and an enhancement of the monocyte differentiation. Combinations of antioxidants with deltanoids could dissociate the oxidative stress and differentiation.
Introduction
1α,25-dihydroxyvitamin D 3 (VD 3 ) is well known for its regulatory role in the modulation of proliferation and differentiation in several normal and malignant cell types (1) . In vivo and in vitro anticancer activities of VD 3 have been commonly attributed to cytostatic and cytotoxic effects on cancer cells. VD 3 
induces apoptosis in breast cancer cells and decreases invasiveness of a number of cell lines in vivo.
In vitro studies demonstrated that VD 3 inhibits cell growth and promotes cell differentiation in tumor cell types such as breast, colon, prostate, glioma, pancreas and neuroblastoma (2, 3) . Differentiation of immature myeloid cells into granulocytic-monocytic lineages resulted in the appearance of specific markers in presence of different agents (4) . VD 3 induces HL60 cells to differentiate into mature myeloid cells with loss of proliferative capacity to acquire a monocyte-like phenotype (5) . As hematopoietic stem cells show lower stage of differentiation in various lineages, their immunophenotype changes could be analyzed by different markers. In leukemic cells, the anti-proliferative capacity was accompanied by a marked increase in the expression of differentiation markers such as CD14 or CD11b (6) . VD 3 binds to a vitamin D receptor (VDR) and to an uncharacterized membrane receptor that interacts with protein kinase C (PKC) and activates mitogen activated protein kinases (MAPKs) (7) . Several studies have shown that HL60 cell differentiation requires the involvement of complex systems such as enzymatic translocation and activation (phospholipase C, phosphatidylinositol 3-kinase, protein kinase C). VD 3 effects involve fast activation pathways of kinase proteins especially towards the differentiation process of keratinocytes and myeloid cells.
Among synthesized analogs of VD 3 , Seocalcitol (EB1089) is ~50-200 times more potent than VD 3 in most cancer cells with respect to inhibition of cell proliferation. This analog shows strong anti-proliferative and differentiating activities on cancer cells (1, 2) .
Several antineoplasic agents generate and release free radicals that cause severe cellular damage. Redox cycling leading to oxidative stress has been proposed as one of the mechanisms by which different agents cause damage, particularly at the DNA level and exert their cytotoxicity in different cancer cells (8) . The final damage occurring in target cells will depend on the rate of ROS formation and on the efficiency of cellular defense mechanisms. The proliferative phenotype is essential for the cell response towards oxidative stress (9) . VD 3 or EB1089 displayed a high disposal of oxidant features and consequently the ability to cause release of reactive oxygen species (ROS) (10, 11) . Non-toxic doses of VD 3 could induce active cell death within oxidative stress mechanism, via generation and release of ROS in MCF-7 cells. Our previous study has described the pro-oxidant activities of VD 3 and EB1089 and the relationship between oxidative stress induced by these two agents and cellular autofluorescence (12) . Doxorubicin (Dox) is a chemotherapeutic agent useful in treating various cancers. Dox is a quinone-containing anthracycline chemotherapeutic and is known to produce ROS in the heart (13) . VD 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage (14) . This treatment can induce serious side-effects in various tissues, including brain, in addition to known cardiotoxic effects, which limit its successful use in chemotherapy.
Antioxidant supplementation to anticancer drugs decreases oxidative DNA damage in human cells. N-acetyl-cysteine (NAC), superoxide dismutase (SOD) and catalase (CAT) are strongly involved in cellular defences against the oxidative damage caused by anticancer drugs. NAC is thought to act by raising intracellular concentrations of GSH and by the direct scavenging of ROS (15, 16) . SOD represents the first line of defense of the cellular antioxidant system against the oxidative damage mediated by superoxide radicals, removing superoxides by catalysing the dismutation of two superoxide radicals to yield hydrogen peroxide (H 2 O 2 ). This ROS is finally transformed into H 2 O and oxygen by CAT (14) .
As regards the myeloid differentiation and the ROS generation, this study aimed to compare VD 3 and EB1089 activities. To enhance differentiation and to limit ROS generation, deltanoids were supplemented with doxorubicin and antioxidants. These association results determined whether oxidative stress and monocyte differentiation could be dissociated.
Materials and methods
Cell lines and culture conditions. Human promyelocytic HL60 leukemia cell line was purchased from the American Type Culture Collection (Rockville, MD, USA). These HL60 cells were grown in a 5% CO 2 atmosphere at 37˚C in RPMI-1640 (1X) medium (Bio-Wittaker, France) with L-glutamin, supplemented with 15% fetal calf serum (FCS) (Gibco-BRL, UK). Cell growth and viability were assessed utilizing the trypan blue exclusion technique (Sigma, France). Cells were routinely examined for mycoplasma contamination.
Chemicals. VD 3 was purchased from Sigma. EB1089 was a generously gift provided by Dr Lise Binderup from Leo Pharmaceuticals Products (Ballerup, Denmark). VD 3 was diluted in absolute ethanol at 10 μM stock solution. EB1089 was supplied as solution diluted in isopropanol (2-propanol) at 4x10 -3 M. Dilutions were performed in absolute ethanol to give stock solutions of 100 μM. The aliquots of stock solutions from both compounds were stored at -20˚C, protected from light. The final ethanol concentration was 0.1% in the culture medium and had no effect on either cell growth or oxidative stress. Doxorubicin (Dox), used as hydrochloride, was prepared as 10 -3 M stock solution (R. Bellon, France) in distilled water and stored at -20˚C. N-acetyl cysteine (NAC), superoxide dismutase (SOD) and catalase (CAT) were purchased from Sigma. NAC was dissolved in phosphate buffer saline (PBS) 1X to form a 1 M stock solution and the pH was adjusted to 7.3 with sodium hydroxide solution. Both SOD and CAT enzymes were also dissolved in PBS 1X to get stock solutions at 10 5 U/ml and 15x10 3 U/ml, respectively. All antioxidant agents were freshly prepared and added to the cell culture medium 1 h before VD 3 or EB1089 incubation.
Determination of cell differentiation. HL60 cell differentiation was assessed by nitroblue tetrazolium reduction assay (NBT). This assay is based on the ability of mature cells (differentiated cells) to reduce tetrazolium salts into formazan beads, due to the superoxide anions they produce upon stimulation with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Sigma). To measure the NBT reduction, 2x10 5 cells were harvested by two centrifugations (400 g, 10 min) and incubated with 200 μl solution containing RPMI-1640, FCS, 1% NBT (Sigma) and 100 nM TPA for 30 min at 37˚C in the dark. Then, cells were examined by optical microscopy. The percentage of purplish cells, indicative of formazan beads presence, was assessed in comparison with untreated cells. At least 300 cells were counted for each experiment.
Measurement of ROS release by fluorescence spectroscopy.
The 2',7'-dichlorodihydrofluorescein diacetate (H 2 -DCFDA) probe (Molecular Probes, France) has the ability to detect ROS production in situ. The cell-permeant form, H 2 -DCFDA, rapidly diffuses through the cell membrane and then is hydrolyzed by intracellular esterases to an oxidativesensitive form, dichlorodihydrofluorescein (H 2 -DCF). In the cytosol, oxidation of H 2 -DCF leads to a fluorescent compound, dichlorofluorescein (DCF) with a fluorescence intensity proportional to intracellular ROS (16) . H 2 O 2 , a well known agent for its oxidative property, was used as a positive marker of oxidative stress.
This fluorescent dye allowed to determine ROS release in HL60 cells, untreated or treated VD 3 or EB1089. Briefly, after treatment, HL60 cells were washed and re-suspended at 10 6 cells/ml in RPMI-1640 without FCS and phenol red. Then, 10 μM H 2 -DCFDA probe was added to each plate at a final volume of 2 ml. Cells were incubated for 45 min at 37˚C in the dark. A second wash was made before the fluorescence analysis using spectrometer at 488 nm intensity excitation λ ex and 516 nm emission λ em . Results, in arbitrary fluorescence units (AFU), were expressed according to the ratio [(AFUtreated cells)/(AFU control cells)] x100.
Statistical analysis. The data, presented as mean ± SD, were obtained from at least three independent experiments. Significant differences were determined using the Student's t-test (p<0.05 was considered to indicate significant differences).
RNA extraction and RT-PCR analysis. HL60 cells were exposed to the following treatments: VD 3 (1-10-100 nM); EB1089 (0.1-1-10 nM) and antioxidant agents (NAC 10 mM, CAT 2000 U/ml, SOD 50 U/ml) for the indicated times. Total RNAs from 5x10 6 cells were isolated using Tri Reagent™ (Sigma). For RT-PCR, aliquots (1 μg) of total RNA were incubated with 2 μl of a mix containing 10 mM dNTP (Boehringer, France), 2 μl buffer 10X, 1 μl of a 500 μg/μl random hexadeoxynucleotide primers (RH), 4 μl of 25 mM MgCl 2 , 0.5 μl of human placenta ribonuclease inhibitor (HPRI: Amersham, France) at 40 U/μl plus 0.42 μl of 24 U/μl Moloney murine leukemia virus reverse transcription (M-MLV reverse transcriptase, Gibco-BRL, France) and RNase/DNasefree water to get a final volume of 20 μl. The samples were kept for 10 min at room temperature, then incubated 1 h at 42˚C and 5 min at 95˚C. RNAs were transcribed into cDNA which were stored at -20˚C, after adding 180 μl of DNAse/RNAse-free water. PCR were performed with 1/20 volume of the reverse transcription reaction for amplification. These amplifications were performed in a total volume of 50 μl containing 5 μl of buffer 10X, 1 μl of 10 mM dNTP, 4 μl of 25 mM of MgCl 2 , 28.8 μl of DNase/RNase-free water, 5 U/μl of Taq DNA polymerase (Invitrogen Life Technologies, France) and 1 μg/μl of primers specific to CD14 and GAPDH genes as follows: CD14 (5'-TAAAGGAC TGCCAGCCAAGC-3' and 5'-AGCCAAGGCAGTTTGAG TGC-3'), GAPDH (5'-CTCTGCCCCCTCTGCTGATGC-3' and 5'-CCATCACGCCACAGTTTCCCG-3'). Amplification profiles included denaturation at 95˚C for 30 sec, primer annealing at 58˚C for 30 sec, and extension at 72˚C for 30 sec. All the amplifications were performed with 30 cycles for CD14 and GAPDH. After PCR, reaction mixtures were analyzed by a 2% agarose gel electrophoresis. In order to ensure total absence of any contamination negative controls, no RNA and no cDNA, were included in the RT-PCR reactions. After incubation, the cells were washed twice in PBS and re-suspended in 500 μl PBS 1X containing 1% paraformaldehyde and stored at 4˚C, always protected from light. As negative controls, FITC-labeled MsIgM for CD14 and PElabeled IgG1 for CD71 were used to set threshold parameters. In each sample, at least 10000 cells were collected and analyzed by a FACS Calibur flow cytometer (Becton Dickinson, France).
Results
Modulation of functional differentiation. VD 3 and EB1089-induced differentiation of HL60 cells into monocytic lineage was studied by expression of mRNA, protein CD14 and functional differentiation using nitroblue tetrazolium assay (NBT). The effects of VD 3 and EB1089 were studied on HL60 cell differentiation, using the NBT assay. Fig. 1 the doxorubicin capacity to increase the differentiation activity of VD 3 or EB1089. HL60 cells were incubated with 15 nM doxorubicin for 1 h before a continuous exposure with VD 3 (1-100 nM) or EB1089 (0.1-10 nM) for 72 h. The percentage of NBT + cells was unaffected by doxorubicin when associated with VD 3 , as compared with VD 3 alone (Fig. 1) . On the contrary, for 0.1 nM EB1089-treated cells, 15 nM doxorubicin induced an increase of NBT + cell percentage from 29% to 87%. Note that 15 nM doxorubicin exposure has no effect on cell differentiation and viability. VD 3 or EB1089 were also associated with 10 nM NAC, 50 U/ml SOD or 2000 U/ml CAT (Fig. 2) . Compared to VD 3 and EB1089 treatments, these associations induced a slight increase of NBT + cells. The highest effect occurred in the case of the EB1089-NAC association. Each antioxidant alone induced no growth inhibitory effect and <3% of NBT + cells (data not shown).
Modulation of mRNA CD14 and CD14 antigen expression.
The mRNA CD14 antigen expression was analyzed during HL60 monocytic differentiation. During treatments with VD 3 or EB1089, mRNA levels for ubiquitary transcripts GAPDH did not vary significantly. After total RNA isolation and RT-PCR, mRNA CD14 levels were slight for untreated cells and 1 nM VD 3 (Fig. 3A) . A significant increase of 40-and 50-fold in CD14 gene expression was observed for 10 and 100 nM VD 3 (Fig. 3A) . The lowest 0.1 nM concentration of EB1089 induced a marked CD14 gene expression which was 40-fold higher than control cells (Fig. 3B) . This result confirms the higher differentiating potential generated by EB1089, as compared with VD 3 . The modulation of mRNA CD14 gene expression by NAC, SOD and CAT antioxidants is presented on Fig. 4 . After a 72 h incubation of VD 3 or EB1089 with antioxidant agents (10 nM NAC, 50 U/ml SOD or 2000 U/ml CAT), CD14 gene expression showed a modulation of mRNA. Semi-quantification displays a significant increased expression of mRNA CD14 in co-treated cells (Fig. 4) . In the absence of VD 3 or EB1089, each antioxidant was unable to stimulate significantly CD14 gene expression, as compared to untreated cells (data not shown). Moreover, cells were treated with VD 3 or EB1089, associated with 15 nM doxorubicin. The EB1089-doxorubicin association induced a significant increase of mRNA expression, as compared with EB1089 (0.1 nM) (Fig. 4B) .
After a 72 h exposure to VD 3 or EB1089, the induction of the CD14 monocyte marker to immature HL60 cells was studied by flow cytometry (Table I ). In the absence of a differentiation stimulation, only 2% of cells were CD14 + . The VD 3 treatment induced 12% of CD14 + cells, that increased significantly to 19% and 20% when associated with NAC and SOD antioxidants, respectively.
Modulation of ROS release. It has been well described that some differentiation inducing agents such as VD 3 and the EB1089 analog display oxidant features and consequently ROS release. Evaluation of ROS was performed by the H 2 -DCFDA fluorescent dye, whose emission intensity was expressed as a percentage of control cell intensity. VD 3 -or EB1089-treated HL60 cells showed an increase of H 2 -DCFDA fluorescence intensity (p<0.05), that corresponds to an oxidative effect.
The effects of NAC, SOD, CAT antioxidants to modulate ROS release in VD 3 -or EB1089-treated cells was investigated (Fig. 5 ). Results are expressed as H 2 DCFDA fluorescence intensity, with respect to untreated cells (100%). Cells were pre-treated for 1 h with each antioxidant before addition of VD 3 or EB1089. Antioxidants induced a decrease (p<0.05) in ROS release generated by VD 3 or EB1089 near the level of untreated cells. This suggests a protective role of these antioxidant agents against VD 3 and EB1089 oxidative cytotoxicity.
HL60 were treated with 15 nM doxorubicin to induce oxidative stress (Fig. 5) . We investigated a possible additive effect of doxorubicin in combination with VD 3 or EB1089, in Table I. Percentage of CD14 + cells induced by VD 3 or EB1089, associated with NAC, SOD or CAT antioxidants. - modulating oxidative stress. The association with doxorubicin induced a significant increase of ROS release (p<0.05) versus 1 nM VD 3 -and 0.1 nM EB1089-treated cells (Fig. 5 ). An additive ROS release (p<0.05) was observed in comparison with individual effects of doxorubicin and VD 3 .
Discussion
The comparison of VD 3 with its analog has shown that EB1089 was more effective than the native hormone with 10-100 lower concentrations. Similar results have been described for U937 monocytic cells, MCF-7 carcinoma cells and HaCaT keratinocytes (17, 18) . These results are due to enhanced effects of EB1089 to cell cycle regulation through c-myc, c-fos, p21 and p53. In MCF-7 cancer cells, EB1089 induced a higher decrease of estrogen receptors than VD 3 (19) . According to the drug used, HL60 differentiates either to granulocyte, monocyte or macrophage lineage. In a first step, HL60 cell differentiation was appraised by using the NBT test. The number of differentiated cells (NBT + ) increases for 48 h of the treatment. To detail VD 3 and EB1089 properties, the NBT test was completed by CD14 expression. CD14 antigen was highly expressed by monocyte and macrophage lineages. Following the treatment with 10 nM VD 3 or 0.1 nM EB1089 for 72 h, the mRNA CD14 and CD14 expressions strongly increased, associated with the abolishment of CD71 expression (data not shown). A time course study demonstrated that mRNA CD14 expression occurred after 6 h VD 3 treatment, whereas CD14 expression and NBT + cells were not observed after this time period. VD 3 and EB1089 present oxidative properties displayed by ROS release which is dose-and time-dependent. We confirm that one biological mechanism of VD 3 and EB1089 is based on ROS induction (11) . The comparison of EB1089 and VD 3 activities indicates that EB1089 is as active as VD 3 , with 10-100 lower concentrations. VD 3 brought an increase in the cellular redox state as reflected in the ratio between oxidized and reduced glutathione and glyceraldehyde-3-phosphate dehydrogenase. In addition, the expression of the antioxidant enzyme Cu/Zn superoxide dismutase decreased (20) . These reactive oxygen species are involved in the anticancer activity of vitamin D on its own and in its crosstalk with other anticancer modalities. It has been described that one mechanism of action leading to apoptosis by anticancer agent is based on ROS generation and release. The effect of VD 3 to the damage inflicted on breast cancer cells has been examined by the direct action of ROS. VD 3 sensitizes to ROS-induced death by affecting both caspasedependent and -independent modes of cell death upstream to mitochondrial damage (21) . This increased oxidative stress by VD 3 was manifested by glutathione depletion and was abolished by exposure to the thiol antioxidant NAC.
Recent evidence suggested that ROS and antioxidant enzymes could be associated with cell differentiation and disease (22) . In this study, SOD, CAT, NAC antioxidants were associated with VD 3 and EB1089 to modulate their differentiation activity. After 72 h of exposure, NAC, SOD and CAT slightly increased the percentage of NBT + cells, CD14 expression and mRNA CD14 expression of VD 3 and EB1089 treated cells. These antioxidants highly reduced ROS generated by VD 3 and EB1089 drugs, suggesting a protective role of these antioxidant agents against latter VD 3 and EB1089-induced cytotoxicity. Thus, the modulation of the cell redox status influences the induction of differentiation. The NAC antioxidant, a sulfhydryl reductant, reduces oxidised glutathione, as well as being a precursor of intracellular cysteine and glutathione. Moreover, NAC regulates the conversion from proliferation to differentiation at a transcriptional level (23) . The addition of antioxidants to VD 3 activated the JNK pathway as indicated by increased phosphorylation of c-jun and ATF-2. The potentiation of differentiation by antioxidants was inhibited by JNK inhibitor SP600125 (24) . Thus, the JNK-AP1 pathway has an important role in the potentiation of VD 3 -induced differentiation by antioxidants, and regulates expression of Egr-1 and c-fos (25) . Antioxidants such as polyphenols, carotenoids, tocopherol and lipoic acid also potentiate myeloid differentiation by VD 3 or ATRA (26) . In addition, the antioxidant carnosic acid, a phenolic terpen, increases the potency of VD 3 to subtype JNK pathways. Rather than their various chemical structures, the common property of these antioxidants to decrease ROS would play an important role to modulate differentiation. In order to potentiate VD 3 -induced differentiation, the association with subtoxic doxorubicin concentrations was evaluated. In presence of doxorubicin, differentiation effect (NBT + cells) of EB1089 was clearly enhanced. However, mRNA CD14 and CD14 expressions were not significantly modulated by doxorubicin. VD 3 was associated with other topoisomerase II inhibitors, such as etoposide and mitoxantrone to potentiate more clearly their differentiation activity (27) . The modulation of oxidative stress by doxorubicin was also investigated. VD 3 synergistically enhanced the susceptibility of MCF-7 breast cancer cells to doxorubicin and menadione (14, 28) . In addition, the pre-treatment of cancer cells with VD 3 or EB1089 selectively increased their susceptibility to anticancer cytokines via ROS generation (15) or to all-trans-retinoic acid ATRA (29) . Such combinations may provide useful therapeutic perspectives in the treatment of a variety of cancers.
In conclusion, the antioxidant supplementation inhibits oxidation and slightly increases cell differentiation, induced by VD 3 and EB1089. Combinations of antioxidants with VD 3 could dissociate oxidative stress and monocyte differentiation, and need further evaluation for cancer chemoprevention.
